Future directions of this work include investigation of direct BRD4 gene regulation to better understand the dynamics of BRD4-driven/maintained T cell exhaustion in CLL and inform future use of BET inhibitors as immunomodulatory agents in the management of CLL. This evidence concerns the gene BRD4 and B-cell chronic lymphocytic leukemia.